Tocagen is committed to fighting brain cancer. Recurrent high grade glioma, or HGG, is the most common and aggressive primary brain cancer and often strikes in the prime of life. The total number of new diagnoses of HGG expected in 2019 is about 190,000 worldwide and about 17,000 in the United States, and the two most common forms of HGGs are glioblastoma, or GBM, and anaplastic astrocytoma, or AA.
Standard of care for newly diagnosed HGG is surgical removal of as much of the tumor as possible followed by radiation therapy and an alkylating drug, temozolomide. Unfortunately, HGG recurs in most patients, even after maximal treatment. Patients may find it empowering to plan ahead with their care team to determine which options may be suitable for them in the event of a recurrence, including consideration of a clinical trial.
Tocagen is conducting a Phase 3 clinical trial, called Toca 5, for patients with recurrent GBM or AA who are planning to have their tumor removed surgically. The Toca 5 trial is fully enrolled and not recruiting patients. Tocagen is also conducting a Phase 1b clinical trial, called Toca 6, for patients with advanced cancer. The Toca 6 trial is currently closed to new participants. NRG-BN006, a proposed Phase 2/3 trial for the treatment of patients with newly diagnosed glioblastoma, is expected to begin enrollment in 2019 and will be conducted by NRG Oncology.
Learn more and contact us through our clinical trials page for more information about our ongoing trials.